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Background-—The Framingham Risk Score estimates the 10-year risk of cardiovascular events. However, it performs poorly in
older adults. We evaluated the incremental benefit of adding high-sensitivity cardiac troponin I (hs-cTnI) to the Framingham Risk
Score.
Methods and Results-—The HIMS (Health in Men Study) is a cohort study of community-dwelling men aged 70 to 89 years in
Western Australia. Participants were identified from the electoral roll, with a subset undergoing plasma analysis. Hs-cTnI (Abbott
Architect i2000SR) was measured in 1151 men without prior cardiovascular disease. The Western Australia Data Linkage System
was used to identify incident cardiovascular events. After 10 years of follow-up, 252 men (22%) had a cardiovascular event (CVE+)
and 899 did not (CVE–). The Framingham Risk Score placed 148 (59%) CVE+ and 415 (46%) CVE– in the high-risk category. In CVE–
men, adding hs-cTnI affected the risk categories of 244 (27.2%) men, with 64.8% appropriately reclassified to a lower and 35.2% to
a higher category, which decreased the number of high-risk men in the CVE– to 39%. In CVE+ men, adding hs-cTnI affected the risk
categories of 61 (24.2%), with 50.8% appropriately reclassified to a higher and 49.2% to a lower category and 82.5% remaining
above the 15% risk treatment threshold. The net reclassification index was 0.305 (P<0.001). Adding hs-cTnI increased the C-
statistic modestly from 0.588 (95% CI, 0.552–0.624) to 0.624 (95% CI, 0.589–0.659) and improved model fit (likelihood ratio test,
P<0.001).
Conclusions-—Adding hs-cTnI to the Framingham Risk Score provided incremental prognostic benefit in older men, especially
aiding reclassification of individuals into a lower risk category. ( J Am Heart Assoc. 2019;8:e011818. DOI: 10.1161/JAHA.118.
011818.)
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C ardiovascular disease (CVD) is a major cause of morbid-ity and mortality, which imposes a substantial burden on
healthcare expenditure.1 The Framingham Risk Score (FRS) is
a widely used model to estimate 10-year risk of cardiovas-
cular events and aids in deciding on the use of primary
prevention therapies. However, this was validated in white
middle-aged populations.2 Studies have demonstrated that
the FRS performs poorly in older adults, suggesting that
conventional risk factors are not as predictive of cardiovas-
cular events in older people.3,4
High-sensitivity cardiac troponin I (hs-cTnI) assays can
measure 10-fold lower concentrations with more precision
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than older assays, and are able to accurately quantify cardiac
troponin in 50% of a reference population with a coefficient of
variation of <10% at the 99th percentile.5 Measurable
concentrations of cardiac troponin I and T in the general
population are associated with structural cardiac disease,
heart failure, and an increase in both all-cause and cardio-
vascular morbidity and mortality.6–15 Furthermore, in stable
outpatients with coronary artery disease, hs-cTnI can provide
prognostic information regarding risk of future myocardial
infarction and cardiovascular mortality.16,17 However, few
studies have evaluated hs-cTnI as a prognostic indicator for
older people.6,18
The aim of this study was to evaluate the incremental
benefit of adding hs-cTnI to the FRS for cardiovascular risk
stratification in older men.
Methods
This study was conducted as part of the HIMS (Health in Men
Study), which is a cohort study of community-dwelling men
aged 70 to 89 years from Perth, Western Australia.19 The
HIMS recruitment process and study population have been
previously described in detail.19 In brief, HIMS was conducted
in 2 waves; 12 203 men completed a questionnaire and
underwent physical examination between 1996 and 1999,
and 4248 of these men were reassessed and had venesection
between 2001 and 2004.19 The population for this arm of the
study was selected from wave 2, as these participants had
undergone pathology testing and had stored plasma samples.
All participants provided written consent, and the University
of Western Australia Human Research Ethics Committee
approved the study.19 Because of the sensitive nature of the
data collected for this study, requests to access the data set
from qualified researchers trained in human subject confi-
dentiality protocols may be sent to the Western Australian
Centre for Health & Ageing at wacha@uwa.edu.au.
Physical assessments were performed by research nurses
and included height, weight, and blood pressure.19 Partici-
pants completed a medical history survey and various
questionnaires to assess smoking status, activity, memory,
and psychosocial factors as previously described.19
Hypertension was defined as blood pressure of ≥140/
90 mm Hg, hypertension listed in the medical history, or the
use of antihypertensive medications.20 Diabetes mellitus was
defined as fasting blood glucose of ≥7.0 mmol/L, nonfasting
blood glucose of ≥11.1 mmol/L, a stated history of diabetes
mellitus, or the use of glucose-lowering medication.20
Dyslipidemia was defined as a fasting high-density lipopro-
tein of <0.9 mmol/L, low-density lipoprotein of ≥3.4 mmol/
L, triglycerides of ≥1.8 mmol/L, total cholesterol of
≥5.5 mmol/L, or the use of lipid-lowering therapy.20
Preexisting CVD was defined as a self-reported history of
angina, myocardial infarction, stroke, or abdominal aortic
aneurysm.20 The FRS to estimate 10-year cardiovascular
event risk was calculated only for men without prior CVD.
Blood samples were collected between 8:00 AM and 10:30
AM. Samples collected into lithium heparin plasma separator
(gel) tubes were promptly centrifuged at 2000g for
10 minutes. Cholesterol, triglycerides, high-density lipopro-
tein cholesterol, and creatinine were analyzed on the day of
collection in an accredited laboratory. Low-density lipoprotein
cholesterol was calculated using the Friedewald equation.21
Samples of serum were prepared and frozen at 80°C in 3
0.8-mL aliquots.19 Measurement of cardiac troponin I was
done on one of these serum aliquots, which was thawed and
recentrifuged prior to analysis. Samples were analyzed for
cardiac troponin I using an Abbott Architect i2000SR assay
over several days using a single reagent lot. This assay has a
coefficient of variation of 10% at 6 ng/L in this laboratory.22
The Western Australia Data Linkage System was used to
determine occurrence of cardiovascular events and death
over 10 years of follow-up.20,23 This system collates informa-
tion from hospital morbidity and mortality data, emergency
departments, and the death registry at 6-month intervals.23
The primary outcome measure, cardiovascular events over
10 years, was defined as a composite of coronary heart
disease events (including coronary death, myocardial infarc-
tion, coronary insufficiency, and angina), cerebrovascular
disease events (including ischemic stroke, hemorrhagic
stroke, and transient ischemic attack), peripheral artery
disease events (including intermittent claudication), and heart
failure.
Clinical Perspective
What Is New?
• Addition of high-sensitivity cardiac troponin I to the
Framingham Risk Score significantly improved risk predic-
tion in older men.
• There was a greater impact on the predicted risks for the
men who did not experience a cardiovascular event during
follow-up than in men who did.
• The new model was able to identify a cohort previously
misclassified as high cardiovascular risk who had a lower
risk of cardiovascular disease over a 10-year period.
What Are the Clinical Implications?
• The ability to identify a group of older adults with a relatively
low risk of cardiovascular disease using high-sensitivity
cardiac troponin I would allow more judicious use of
preventative medications in this age group, thus avoiding
side effects and drug-interactions.
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Statistical analysis was performed using SAS 9.4 (SAS
Institute, Cary, NC) and STATA (StataCorp, College Station,
TX). Categorical variables are described as absolute numbers
and percentages. Continuous variables are described as mean
and SD, while skewed data are also described as median and
interquartile range. The 99th percentile value for hs-cTnI was
calculated as the absolute single upper 99th percentile value
using hs-cTnI results for men without preexisting CVD at
baseline. Nonparametric data were compared using the
Wilcoxon rank-sum test. A P<0.05 was used to defined
statistical significance. Logistic regression was used to assess
the association of hs-cTnI with 10-year mortality. Cox
proportional hazards regression modeling was used to
examine the association between covariates of the FRS and
cardiovascular events over 10 years. Hs-cTnI was then added
as a continuous predictor to the Cox regression model to form
a new model. The traditional FRS was compared with the new
model using the C-statistic, which measures discriminatory
ability by indicating the correct ranking of each individual’s
risk, and the likelihood ratio test of improved model fit.
Predicted 10-year risks were also compared using the
continuous net reclassification improvement, which quantifies
improvement offered by a new marker.24 Density plots,
receiver operating curves, and recalibration plots were used
to graphically display differences between models.24 Reclas-
sification tables were constructed for people who did or did
not experience a cardiovascular event during follow-up, where
comparison is made between quartiles of risk calculated with
the FRS and the new model.24
Results
A total of 4248 men contributed data to the second wave of
HIMS. The majority were born in Australia (62.0%), Northern
Europe (26.7%), and the Mediterranean (5.2%).19 During a
planned analysis of 4248 patient samples for another study,
the last 2111 samples were accessible for analysis of hs-cTnI,
which then formed the cohort of this study. There were 1137
men aged 70 to 74 years, 843 aged 75 to 79 years, and 131
aged 80 years or older. Baseline characteristics are presented
in Table 1.
The hs-cTnI distribution for the entire cohort (n=2111)
was nonparametric, as shown in Figure 1. Overall, the mean
hs-cTnI was 9.4 ng/L, with a median of 5.9 ng/L and an
interquartile range of 4.6 ng/L. The 25th and 75th per-
centiles were 4.2 and 8.8 ng/L, respectively. There were 42
men with hs-cTnI concentrations ≥40.0 ng/L, with a range
of 40.7 to 398.5 ng/L. Increased age, current smoking,
presence of baseline comorbidities, and CVD were associ-
ated with increased hs-cTnI concentration, as presented in
Table 2.
Figure 1 also shows the distribution of hs-cTnI concentra-
tions for men without CVD (n=1151) at baseline. The mean
hs-cTnI for this group was 6.9 ng/L, with a median of 5.3 ng/
L and an interquartile range of 3.5 ng/L. The 25th and 75th
percentiles were 3.9 and 7.4 ng/L, respectively. The 99th
percentile for all men without CVD was 30.0 ng/L (95%CI,
24.1–50.3 ng/L). There were 9 men with hs-cTnI concentra-
tions ≥40.0 ng/L, with a range of 41.6 to 216.2 ng/L.
All-cause mortality after 10 years was 23.2% and CVD
mortality was 7.8% in the men without prior CVD. The FRS to
estimate 10-year cardiovascular event risk was calculated for
men without prior CVD (n=1151).2 After 10 years of follow-
up, 252 (22%) had a cardiovascular event (CVE+) and the
remaining 899 (78%) did not (CVE). The score placed 148
(59%) CVE+ men and 415 (46%) CVE men in the high-risk
category (10-year risk >20%).
The addition of log(troponin) increased the C-statistic
modestly from 0.588 (95% CI, 0.552–0.624) to 0.624 (95% CI,
Table 1. Baseline Characteristics
Characteristic*
Without CVD
(n=1151)
With CVD
(n=960) Overall (n=2111)
Age, y
70 to 74 700 (60.8) 437 (45.5) 1137 (53.9)
75 to 79 437 (38.0) 406 (42.3) 843 (39.9)
>80 14 (1.2) 117 (12.2) 131 (6.2)
Smoking status
Never 424 (36.8) 280 (29.1) 704 (33.3)
Former 656 (57.0) 620 (64.6) 1276 (60.4)
Current 71 (6.2) 60 (6.3) 131 (6.2)
BMI, kg/m2
<20 21 (1.8) 22 (2.3) 43 (2.0)
20 to <25 374 (32.5) 272 (28.4) 646 (30.6)
25 to <30 599 (52.0) 493 (51.5) 1092 (51.8)
≥30 157 (13.7) 170 (17.8) 327 (15.5)
Diabetes mellitus 137 (11.9) 187 (19.5) 324 (15.3)
Hypertension 450 (39.1) 579 (60.3) 1029 (48.7)
Dyslipidemia 433 (38.9) 674 (72.2) 1107 (54.1)
Malignancy 223 (19.4) 191 (19.9) 414 (19.6)
Biochemistry
Troponin, ng/L 5.3 (3.5) 7.0 (6.8) 5.9 (4.6)
Creatinine, lmol/L 90.5 (20.0) 101.7 (36.9) 95.6 (29.5)
eGFR, mL/min
per 1.73 m2
79.0 (16.5) 71.9 (19.2) 75.8 (18.2)
BMI indicates body mass index; CVD, cardiovascular disease; eGFR, estimated
glomerular filtration rate.
*Troponin is expressed as median (interquartile range). Creatinine and eGFR are
expressed as mean (SD). All other variables are expressed as count (%).
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0.589–0.659) but significantly improved model fit (likelihood
ratio test of improvement in fit, P<0.001). Receiver operating
characteristic curves showing improvement in the model with
addition of hs-cTnI (C-statistic 0.624 versus 0.588) is shown
in Figure 2. Comparison of the 2 models using regression
analysis is presented in Table 3. The addition of hs-cTnI to the
Figure 1. The distribution of high-sensitivity cardiac troponin I for the entire cohort (top) and for men
without prior cardiovascular disease (CVD) (bottom).
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FRS adjusted for only the effect of age, with no effect on the
other covariates.
The predicted risk using the FRS and with the addition of
hs-cTnI are presented as reclassification tables (Tables 4
and 5). The net reclassification index was 0.305 (P<0.001).
There was a greater impact on the predicted risk in the CVE
men than in CVE+ men. In the 899 CVE men, the addition of
hs-cTnI affected the risk categories of 244 (27.2%). In these
men, 64.8% were appropriately reclassified to a lower
category and 35.2% to a higher category. This decreased
the number of men in the high-risk category from 46% with
the FRS model to 39% with the FRS plus hs-cTnI model. In the
252 CVE+ men, the addition of hs-cTnI affected the risk
categories of 61 (24.2%). In these men, 50.8% were appro-
priately reclassified to a higher risk category and 49.2% to a
lower risk category, with 82.5% remaining above the treat-
ment threshold of 15% risk.
Density plots showing improvements in predicted risk for
CVE and for CVD+ men are presented in Figure 3.
Calibration plots showing improvement in the prediction of
10-year risk of cardiovascular events for those CVE and
CVD+ men are shown in Figure 4.
A modified 10-year CVD risk calculator was derived using
the original FRS variables (Table S1) and with the addition of
hs-cTnI (Table S2). The risk associated with individual scores
is shown in Tables S3 and S4. Hs-cTnI was independently
associated with risk of cardiovascular events, even at
concentrations considerably lower than the 99th percentile,
with increasing hs-cTnI concentrations predicting elevated
cardiovascular risk. Furthermore, hs-cTnI had a greater impact
on the risk score compared with other covariates due to the
wider range of points allocated, which allowed for a wider
range of 10-year risk estimates (Tables S1 through S4).
Discussion
This is the first study to demonstrate that the addition of hs-
cTnI to the FRS significantly improves the prediction of
cardiovascular events in this cohort, and identifies a cohort of
elderly men previously misclassified as high cardiovascular
Table 2. Troponin Concentration by Baseline Characteristic
Characteristic Mean (SD)*
25th
Percentile Median
75th
Percentile
Age (y)†
70 to 74 8.9 (22.1) 3.9 5.2 7.8
75 to 79 9.9 (13.3) 4.8 6.6 9.7
≥80 10.6 (7.1) 5.6 8.3 13.9
Smoking status†
Never 8.4 (12.0) 4.1 5.7 8.3
Former 9.8 (20.1) 4.3 6.0 9.3
Current 10.5 (26.7) 4.9 6.8 8.6
BMI (kg/m2)†
<20 6.1 (3.5) 3.6 4.7 7.9
20 to <25 9.0 (18.8) 4.2 5.8 8.6
25 to <30 9.3 (16.5) 4.2 5.8 8.8
≥30 11.0 (23.5) 4.4 6.5 10.1
Diabetes mellitus†
No 9.1 (18.2) 4.2 5.8 8.6
Yes 11.0 (19.0) 4.7 6.5 10.5
Hypertension†
No 8.2 (16.4) 3.9 5.2 7.8
Yes 10.7 (20.1) 4.7 6.6 10.4
Dyslipidemia†
No 8.0 (11.8) 4.1 5.7 8.2
Yes 10.3 (20.3) 4.3 6.3 9.8
Malignancy
No 9.4 (17.5) 4.2 5.9 8.8
Yes 9.3 (21.2) 4.3 6.0 8.8
CVD†
No 6.9 (9.3) 3.9 5.3 7.4
Yes 12.3 (24.9) 4.7 7.0 11.5
BMI indicates body mass index; CVD, cardiovascular disease.
*Troponin concentrations are in ng/L.
†Significant difference in troponin values between groups (P<0.05).
Figure 2. Receiver operating characteristic curves showing
improvement of the cardiovascular disease (CVD) model with
addition of high-sensitivity cardiac troponin I.
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risk who had a lower risk of cardiovascular events over a 10-
year period. There was a greater impact on the predicted
risks for the men who did not experience a cardiovascular
event than in men who did.
The FRS is unable to identify older adults with relatively low
cardiovascular risk, as it attributes points based on age.
Furthermore, the association between conventional risk
factors such as hypertension and hyperlipidemia with CVD
in older adults is not the same as it is for younger
populations.3,4 The original FRS performs relatively poorly in
older men, with a C-statistic of 0.588, found in both the
current study and an American study, compared with a C-
statistic of 0.76 in the Framingham cohort.2,3 The addition of
hs-cTnI to the model resulted in a C-statistic of 0.624 and an
improvement in model fit (likelihood ratio test, P<0.001).
Recently, an Australian study on hs-cTnI in older women
with a mean age of 75 years and a Swedish study on hs-cTnI
in men aged 70 years found that hs-cTnI was independently
associated with cardiovascular events.6,18 Both studies also
found that the addition of cTnI to the FRS may improve risk
prediction.6,18 Using a cohort twice the size and a wider age
range, our study supports the concept that hs-cTnI can aid in
prognostic discrimination and, in addition, can significantly
improve reclassification.
The ability to identify a group of older adults with a
relatively low risk of cardiovascular events using hs-cTnI
would allow more judicious use of preventative medications in
this age group, thus avoiding side effects and drug interac-
tions. There is currently insufficient evidence for statin use in
older adults for primary prevention, with some studies
showing a possible increase in mortality in this setting.25,26
On the other hand, reclassification into a high-risk category
may prompt clinicians to consider preventative therapies.10,13
In a randomized controlled trial of patients without CVD and a
normal cholesterol, those with higher concentrations of hs-
cTnI had a greater reduction in absolute risk of cardiovacsular
events while on rosuvastatin therapy.14 This was however,
conducted in a relatively younger cohort.
Our study also establishes the 99th percentile of hs-cTnI
using the Abbott Architect assay in this community-based
cohort of men aged over 70 years. Various studies have
published different results for the 99th percentile of hs-cTnI,
which can be due to differences in reference population
selection.27 The 99th percentile for older men without a
history of self-reported CVD in our study was 30.0 ng/L,
which is similar to that reported in other studies of people
from a wide range of age groups.28,29 In addition, there have
been studies in presumably healthy and considerably younger
men that have quoted slightly higher concentrations of
between 33 and 36 ng/L using the same assay.30–33
However, the 25th percentile, median and 75th percentile
Table 4. Predicted Risk in Men Who Did Not Experience a Cardiovascular Event
Framingham
Risk Score
Framingham Risk Score Plus Troponin I
6% to 10% 11% to 15% 16% to 20% >20% Total
6% to 10% 0 (0.00) 3 (0.26) 0 (0.00) 0 (0.00) 3 (0.33)
11% to 15% 33 (2.87) 62 (5.39) 19 (1.65) 10 (0.87) 124 (13.8)
16% to 20% 18 (1.56) 145 (12.6) 132 (11.5) 62 (5.39) 357 (39.7)
>20% 1 (0.09) 16 (1.39) 124 (10.8) 274 (23.8) 415 (46.2)
Total 52 (5.78) 226 (25.1) 275 (30.6) 346 (38.5) 899 (100)
Table 3. Regression Analysis for Comparison of Models
Variable
Framingham Model
Framingham Model
Plus log(troponin)
b SE b SE
log(age) 5.134 2.03 3.042 2.05
log(cholesterol) 0.951 0.42 0.793 0.42
log(HDL) 0.414 0.28 0.395 0.28
log(SBP), untreated 0.727 0.60 1.105 0.59
log(SBP), treated 2.130 0.89 2.184 0.87
Hypertension treated
No 0.000 0.000
Yes 0.322 0.15 0.230 0.15
Current smoker
No 0.000 0.000
Yes 0.350 0.25 0.254 0.25
Prior diabetes mellitus
No 0.000 0.000
Yes 0.182 0.19 0.081 0.19
log(troponin) 0.619 0.10
AIC 3483.326 3453.170
BIC 3523.713 3498.605
C 0.588 0.624
AIC indicates Akaike Information Criterion; BIC, Bayesian Information Criterion; C, C-
statistic; HDL, high-density lipoprotein; SBP, systolic blood pressure.
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of 3.9, 5.3, and 7.4 ng/L, respectively, in our study is higher
than 2.0, 3.2, and 4.6 ng/L or 1.5, 2.7, and 4.6 ng/L,
respectively, in other studies in younger adults.13,31
Some studies have found that elevations of hs-cTnI are
commonly seen in older adults, independent of comorbidi-
ties.34 As such, there is debate over whether older adults
should have higher diagnostic thresholds for the diagnosis of
acute myocardial infarction.35,36 Our findings demonstrate
that the 99th percentile of hs-cTnI in healthy older men is
comparable to that in healthy younger men.30–33 Taken
together, these findings suggest that increasing cardiac
troponin I concentrations may reflect concurrent morbidity
or progressive myocardial impairment rather than a benign
process associated with aging.6
Additionally, we found that hs-cTnI increased with age,
comorbidities, and the presence of CVD. Although hs-cTnI was
greater in current smokers compared with never smokers, as
one may expect, this finding is in contrast with that from
another large cohort study.37 The complex relationship
between smoking, hs-cTnI, and cardiovascular risk therefore
requires further elucidation in subsequent studies.
The strengths of our study include the large population and
wide age range for an older population. This study also
includes a long period of follow-up, in excess of 10 years in
older adults, which has not been previously reported.
Moreover, the study had very robust data linkage ensuring
that mortality and morbidity data are captured. HIMS
benefited from an extensive initial recruitment process, as
participants were invited from the electoral role, where
enrollment to vote is compulsory in Australia. Furthermore,
the study involved collection of very extensive baseline data
from which to draw associations. However, further validation
studies are required for our modified risk prediction model.
Limitations include that this cohort is predominantly white
in origin, includes only men, and is located in a major
metropolitan area. Our findings would need to be confirmed in
other populations. Not all participants in the second wave of
the HIMS had hs-cTnI measured, and all results are based on
blood samples collected at a single point in time. It has
previously been shown that dynamic changes in cardiac
troponin are associated with dynamic changes in risk of CVD
mortality, and serial measurements may play a future role in
Figure 3. Density plots showing improvement in predicted risk after addition of high-sensitivity cardiac
troponin I for men who did not experience a cardiovascular disease (CVD) event and for men who
experienced a cardiovascular disease event during follow-up.
Table 5. Predicted Risk in Men Who Experienced a Cardiovascular Event
Framingham Risk Score
Framingham Risk Score Plus Troponin I
6% to 10% 11% to 15% 16% to 20% >20% Total
6% to 10% 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
11% to 15% 3 (0.26) 12 (1.04) 5 (0.43) 4 (0.35) 24 (9.52)
16% to 20% 2 (0.17) 21 (1.82) 33 (2.87) 24 (2.09) 80 (31.7)
>20% 0 (0.00) 6 (0.52) 29 (2.52) 113 (9.8) 148 (58.7)
Total 5 (1.98) 39 (15.5) 67 (26.6) 141 (56.0) 252 (100)
DOI: 10.1161/JAHA.118.011818 Journal of the American Heart Association 7
High-Sensitivity Troponin and Cardiovascular Risk Lan et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on February 25, 2020
risk stratification.6,8,38 In addition, variations in hs-cTnI, such
as that from analytical imprecision, may limit the utility of
single hs-cTnI measurements for risk prediction and the
performance of risk prediction tools that use hs-cTnI. In our
laboratory, the coefficient of variation (analytical imprecision)
for the hs-cTnI assay used is 10% at 6 ng/L.22
We did not study the incremental benefit of adding high-
sensitivity cardiac troponin T to the FRS in our cohort of
patients. However, increased high-sensitivity cardiac troponin
T levels, like hs-cTnI, have been associated with incident heart
failure and cardiovascular mortality in older adults and could
potentially add to current risk prediction scores in this
cohort.8 In addition, the incremental benefit of other
biomarkers such as N-terminal pro-brain–type natriuretic
peptide and C-reactive protein was not studied.7,12,14 Fur-
thermore, residual confounding due to unmeasured clinical
and laboratory prognostic factors or random error are
additional limitations of this study.
We conclude from this study of community-dwelling older
men in Australia that the 99th percentile of hs-cTnI was
comparable to that of younger healthy men seen in previous
studies. Hs-cTnI was associated with 10-year cardiovascular
events and provided incremental prognostic value when
added to the FRS. The combined model especially aided in
reclassification of individuals into a lower risk category and
identifies a group of older adults at a relatively lower risk of
cardiovascular events.
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Table S1. CVD Model Scoring Matrix. 
 
Points Age Total 
Cholesterol 
HDL Current 
Smoker 
Prior 
Diabetes 
SBP Not  
Treated 
SBP 
Treated 
-5       <120 
-4      160+  
-3   60+     
-2      140-159 120-129 
-1   50-59   130-139  
0 70-74 <160 45-49 No No 120-129 130-139 
1   35-44   <120  
2   <35     
3  160-199   Yes  140-159 
4        
5 74-79   Yes    
6  200-239      
7        
8        
9  240-279     160+ 
10 80+ 280+      
11        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D
ow
nloaded from
 http://ahajournals.org by on February 25, 2020
Table S2. CVD plus Troponin Scoring Matrix. 
 
Points Age Total 
Cholesterol 
HDL Current 
Smoker 
Prior 
Diabetes 
SBP Not  
Treated 
SBP 
Treated 
Troponin 
-12       <120  
-11         
-10      160+   
-9         
-8       120-129  
-7         
-6         
-5   60+   140-159   
-4       130-139  
-3         
-2      130-139   
-1   50-59      
0 70-74 <160 45-49 No No 120-129  <2 
1         
2   35-44  Yes <120 140-159  
3         
4   <35      
5 74-79 160-199       
6    Yes     
7         
8        2-2.9  
9  200-239       
10 80+        
11         
12  240-279     160+  
13        3-3.9 
14  280+       
15         
16         
17        4-4.9 
         
20        5-5.9 
22        6-6.9 
24        7-7.9 
26        8-8.9 
28        9-9.9 
         
39        10+ 
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Table S3. CVD Model Scores and associated risk estimates. 
 
CVD Model Score 10-year Risk 
-7 0.09 
-5 0.10 
-4 0.11 
-3 0.12 
-2 0.12 
-1 0.13 
0 0.14 
1 0.15 
2 0.16 
3 0.17 
4 0.18 
5 0.19 
6 0.21 
7 0.22 
8 0.23 
9 0.25 
10 0.26 
11 0.28 
12 0.29 
13 0.31 
14 0.33 
15 0.35 
16 0.37 
17 0.39 
18 0.41 
19 0.43 
20 0.45 
21 0.48 
22 0.50 
24 0.55 
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Table S4. CVD plus Troponin Model Scores and associated risk estimates. 
 
CVD plus Troponin Model Score 
 
10-Year Risk 
-3 0.07 
-2 0.07 
0 0.08 
1 0.08 
2 0.08 
3 0.09 
4 0.09 
5 0.09 
6 0.10 
7 0.10 
8 0.11 
9 0.11 
10 0.11 
11 0.12 
12 0.12 
13 0.13 
14 0.13 
15 0.14 
16 0.14 
17 0.15 
18 0.15 
19 0.16 
20 0.17 
21 0.17 
22 0.18 
23 0.19 
24 0.19 
25 0.20 
26 0.21 
27 0.22 
28 0.22 
29 0.23 
30 0.24 
31 0.25 
32 0.26 
33 0.27 
34 0.28 
35 0.29 
36 0.30 
37 0.31 
38 0.32 
39 0.33 
40 0.34 
41 0.35 
42 0.36 
43 0.37 
44 0.38 
45 0.40 
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46 0.41 
47 0.42 
48 0.44 
49 0.45 
50 0.46 
51 0.48 
52 0.49 
53 0.50 
55 0.53 
56 0.55 
58 0.58 
59 0.59 
60 0.61 
62 0.64 
63 0.65 
65 0.68 
   67             0.71 
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